Biodistribution studies were conducted to verify targeting specificity and pharmacokinetics. In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [Lu-177]Lu-PSMA-617, 18.5 MBq [Lu-177]Lu-PSMA-617, 7.4 MBq [Lu-177]Lu-EB-PSMA-617, and saline (control). A single-...
Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer A new series of bispecific radioligands (BRLs) targeting prostate-specific membrane antigen (PSMA) and gastrin releasing peptide receptor (GRPr), both expressed on prostate cancer...
The chemical similarities of these nuclides and, as a consequence, comparable pharmacokinetics of ligands labeled with 44Sc and 177Lu, respectively, would thus, allow predicting the exact tissue distribution of 177Lu-PSMA-617 based on the PET imaging results obtained with 44Sc-PSMA-617. The ...
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma[Lu-177]Lu-PSMA-617 therapy[Sc-44]Sc-PSMA-617dosimetric analysis
Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys. Am. J. Nucl. Med. Mol. Imaging 2015, 5, 333–347. [Google Scholar] Ahlstedt, J.; Tran, T.A.; Strand, S.-E.; Gram, M.; Åkerström, B. Human Anti-Oxidation ...